Asia Pacific Pharmaceutical Manufacturing Industry Outlook, 2029

The Asia Pacific Pharmaceutical Manufacturing Industry is predicted to reach a staggering USD 5.2 billion by 2030, driven by rise in aging population.

According to publisher, The Asia Pacific pharmaceutical manufacturing industry is a burgeoning giant, fueled by economic growth, rising healthcare awareness, and a growing population. Market Insights: Market Growth Potential: The Asia Pacific pharmaceutical manufacturing industry is predicted to reach a staggering USD 5.2 billion by 2030. Rapid Economic Development: Economic growth in the region is leading to rising disposable incomes, allowing consumers to spend more on healthcare products and propelling domestic pharmaceutical demand. Example: China's growing middle class is increasingly opting for locally-produced medications and supplements. Aging Population: Similar to other regions, Asia Pacific faces a rapidly aging population, particularly in countries like China and Japan. This population segment is more susceptible to age-related health conditions, driving demand for geriatric medications. Example: Increased production of anti-diabetic drugs to address the rising prevalence of Type 2 diabetes among elderly populations in the region. Government Initiatives:

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

Governments in the region are increasingly recognizing the importance of a robust pharmaceutical industry and are investing in research and development (R&D) initiatives. Example: The Indian government launched the "Production Linked Incentive" scheme to attract investment and boost domestic manufacturing of essential drugs. Market Dynamics The Asia Pacific market is a dynamic environment shaped by several key trends: Focus on Localization:

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant

Asian companies are developing and manufacturing pharmaceuticals specifically tailored to the regional market, considering local disease burdens, dietary preferences, and cultural nuances. Example: A Japanese company might develop a diabetes medication with a lower sugar content to cater to patients with specific dietary restrictions. Cost-Effectiveness: Affordability is a key concern in Asia Pacific due to economic disparities within the region. Manufacturers are focusing on cost-effective production methods and generic drug development. Example: Indian generic drug manufacturers are crucial suppliers of affordable essential medications to developing countries worldwide. Contract Manufacturing: Contract manufacturing organizations (CMOs) are playing a growing role, offering established infrastructure and expertise to international pharmaceutical companies seeking cost-competitive production. Example: A Western pharmaceutical company might partner with a CMO in China for large-scale production of a generic antibiotic.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval

Market Segments The Asia Pacific pharmaceutical manufacturing industry can be segmented based on various criteria: Product Type: The market offers a wide range of products, including prescription drugs, over-the-counter medications, vaccines, and biopharmaceuticals. Therapeutic Area: Drugs are developed to target specific therapeutic areas like oncology (cancer), infectious diseases, and cardiovascular diseases. Regional Analysis The Asia Pacific market exhibits significant variations across different regions: East Asia: East Asia, particularly China, Japan, and South Korea, is the dominant leader due to a strong manufacturing base, government support, and a growing domestic market. Example: China is a major producer of active pharmaceutical ingredients (APIs), the raw materials used in drug production. South Asia: South Asia, led by India, is a rapidly growing market due to a large and young population, rising healthcare awareness, and a government focus on affordable generics. Example: India is a major exporter of generic drugs, supplying medications to low- and middle-income countries globally. Southeast Asia: Southeast Asia is an emerging market with significant potential for future growth. As the region's healthcare infrastructure improves and economies develop, the demand for pharmaceuticals is expected to rise. Example: Countries like Vietnam and Thailand are attracting investments in pharmaceutical manufacturing facilities. Key Developments The Asia Pacific market is experiencing continuous innovation: Technological Advancements: The industry is embracing advancements like artificial intelligence (AI) and automation to streamline production processes, improve quality control, and accelerate drug discovery. Example: A Chinese pharmaceutical company might utilize AI-powered systems to analyze vast datasets and identify potential new drug candidates. Focus on Biosimilars: Biosimilars, similar versions of complex biologic drugs, are gaining traction as they offer a more affordable alternative. Example: South Korean companies are investing in biosimilar development to cater to the growing demand for these medications in the region. Competitive Landscape The Asia Pacific market is a competitive landscape with a mix of established players, regional giants, and emerging startups: Multinational Companies: Established multinational pharmaceutical companies like Pfizer, Novartis, and GlaxoSmithKline (GSK) have a strong presence in the region, offering innovative drugs and leveraging their global R&D capabilities. Example: Pfizer might establish a manufacturing facility in India to produce vaccines specifically for the Asian market. Regional Players: Regional giants like Sun Pharma (India), Astellas Pharma (Japan), and Hua Medicine (China) are playing a significant role, with a deep understanding of the regional market needs and strong distribution networks. Example: Sun Pharma is a leading Indian pharmaceutical company known for its affordable generic drugs. Emerging Startups: Local startups are emerging with innovative solutions tailored to the Asian market. These companies might focus on neglected diseases prevalent in the region or develop novel drug delivery systems. Example: A Vietnamese startup might develop a mobile app that connects patients with chronic illnesses to affordable generic medications and online consultations with doctors. Conclusion The Asia Pacific pharmaceutical manufacturing industry is a dynamic and promising market. As economic development continues, healthcare awareness grows, and government support strengthens, the region is poised to become a global leader in pharmaceutical manufacturing. With a focus on localization, cost-effectiveness, and technological advancements, Asia Pacific companies are well-positioned to address regional healthcare needs and contribute to global health security.

Table of Contents

  • 1 Introduction 9
  • 1.1 Industry Definition and Research Scope 9
  • 1.1.1 Industry Definition 9
  • 1.1.2 Research Scope 10
  • 1.2 Research Methodology 13
  • 1.2.1 Overview of Market Research Methodology 13
  • 1.2.2 Market Assumption 14
  • 1.2.3 Secondary Data 14
  • 1.2.4 Primary Data 14
  • 1.2.5 Data Filtration and Model Design 15
  • 1.2.6 Market Size/Share Estimation 16
  • 1.2.7 Research Limitations 17
  • 1.3 Executive Summary 18
  • 2 Market Overview and Dynamics 21
  • 2.1 Market Size and Forecast 21
  • 2.1.1 Impact of COVID-19 on World Economy 24
  • 2.1.2 Impact of COVID-19 on the Market 27
  • 2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 29
  • 2.2 Major Growth Drivers 33
  • 2.3 Market Restraints and Challenges 40
  • 2.4 Emerging Opportunities and Market Trends 43
  • 2.5 Porter’s Fiver Forces Analysis 47
  • 3 Segmentation of Asia Pacific Market by Formulation 51
  • 3.1 Market Overview by Formulation 51
  • 3.2 Tablets 53
  • 3.3 Capsules 54
  • 3.4 Injectable 55
  • 3.5 Sprays 56
  • 3.6 Suspensions 57
  • 3.7 Powders 58
  • 3.8 Other Formulations 59
  • 4 Segmentation of Asia Pacific Market by Route of Administration 60
  • 4.1 Market Overview by Route of Administration 60
  • 4.2 Oral Medicine 62
  • 4.3 Topical Medicine 63
  • 4.4 Parenteral Medicine 64
  • 4.5 Inhalations 65
  • 4.6 Other Routes of Administration 66
  • 5 Segmentation of Asia Pacific Market by Consumer Group 67
  • 5.1 Market Overview by Consumer Group 67
  • 5.2 Children & Adolescents (17 years old and below) 69
  • 5.3 Adults (18-64 years old) 70
  • 5.4 Geriatric (65 years old and above) 71
  • 6 Segmentation of Asia Pacific Market by Therapeutic Application 72
  • 6.1 Market Overview by Therapeutic Application 72
  • 6.2 Cardiovascular Diseases 74
  • 6.3 Pain 75
  • 6.4 Diabetes 76
  • 6.5 Cancer 77
  • 6.6 Respiratory Diseases 78
  • 6.7 Neurological Diseases 79
  • 6.8 Orthopedics 80
  • 6.9 Other Applications 81
  • 7 Segmentation of Asia Pacific Market by Drug Type 82
  • 7.1 Market Overview by Drug Type 82
  • 7.2 Branded Prescription Drugs 84
  • 7.3 Generic Prescription Drugs 85
  • 7.4 OTC Drugs 86
  • 8 Segmentation of Asia Pacific Market by Distribution Channel 87
  • 8.1 Market Overview by Distribution Channel 87
  • 8.2 Retail Channels 89
  • 8.3 Non-retail Channels 90
  • 9 Segmentation of Asia Pacific Market by Manufacturing Facility 91
  • 9.1 Market Overview by Manufacturing Facility 91
  • 9.2 In-house Facility 93
  • 9.3 Outsourced Facility 94
  • 10 Asia-Pacific Market 2022-2032 by Country 95
  • 10.1 Overview of Asia-Pacific Market 95
  • 10.2 Japan 99
  • 10.3 China 102
  • 10.4 Australia 104
  • 10.5 India 107
  • 10.6 South Korea 109
  • 10.7 Rest of APAC Region 111
  • 11 Competitive Landscape 113
  • 11.1 Overview of Key Vendors 113
  • 11.2 New Product Launch, Partnership, Investment, and M&A 116
  • 11.3 Company Profiles 117
  • Abbott Laboratories 117
  • Aenova Group 119
  • Amgen Inc. 123
  • AstraZeneca 126
  • Catalent Inc. 129
  • Eli Lilly and Company 132
  • F. Hoffmann-La Roche Ltd. 134
  • Gilead Sciences Inc. 136
  • GlaxoSmithKline plc 138
  • Johnson & Johnson 142
  • Lonza Group 144
  • Lupin Limited 147
  • Merck & Co., Inc. 149
  • Novartis AG 151
  • Novo Nordisk 153
  • Patheon Inc. 156
  • Pfizer CentreSource 160
  • Sanofi SA 164
  • Takeda 166
  • RELATED REPORTS 168



Table 1. Snapshot of Asia Pacific Pharmaceutical Manufacturing Industry in Balanced Perspective, 2022-2032 19
Table 2. World Pharmaceuticals Output by Region, 2022-2025, annual percentage change 23
Table 3. World Economic Outlook, 2021-2031 25
Table 4. World Economic Outlook, 2021-2023 26
Table 5. Scenarios for Economic Impact of Ukraine Crisis 30
Table 6. World Health Spending by Region, $ bn, 2013-2020 39
Table 7. Main Product Trends and Market Opportunities in Asia Pacific Pharmaceutical Manufacturing Industry 43
Table 8. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 51
Table 9. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 60
Table 10. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group, 2022-2032, $ mn 67
Table 11. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application, 2022-2032, $ mn 72
Table 12. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 82
Table 13. Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel, 2022-2032, $ mn 87
Table 14. Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2022-2032, $ mn 91
Table 15. APAC Pharmaceutical Manufacturing Industry by Country, 2022-2032, $ mn 97
Table 16. Japan Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 101
Table 17. Japan Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 101
Table 18. Japan Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 101
Table 19. China Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 103
Table 20. China Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 103
Table 21. China Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 103
Table 22. Australia Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 106
Table 23. Australia Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 106
Table 24. Australia Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 106
Table 25. India Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 108
Table 26. India Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 108
Table 27. India Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 108
Table 28. South Korea Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 110
Table 29. South Korea Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 110
Table 30. South Korea Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 110
Table 31. Pharmaceutical Manufacturing Industry in Rest of APAC by Country/Region, 2022-2032, $ mn 112
Table 32. Abbott Laboratories: Company Snapshot 117
Table 33. Abbott Laboratories: Business Segmentation 118
Table 34. Abbott Laboratories: Product Portfolio 118
Table 35. Aenova Group: Company Snapshot 119
Table 36. Aenova Group: Business Segmentation 120
Table 37. Aenova Group: Revenue by Product, 2018-2019, thousand Euro 121
Table 38. Aenova Group: Recent Developments 122
Table 39. Amgen Inc.: Company Snapshot 123
Table 40. Amgen Inc.: Approved Drugs or Therapeutic Biologicals 124
Table 41. Astrazeneca: Company Snapshot 126
Table 42. Catalent Inc.: Company Snapshot 129
Table 43. Catalent Inc.: Business Segmentation in 2018 130
Table 44. Catalent Inc.: Product Portfolio 130
Table 45. Catalent Inc.: Revenue, 2018-2020, $ million 131
Table 46. Catalent Inc.: Revenue by Region in 2018 131
Table 47. Eli Lilly and Company: Company Snapshot 132
Table 48. Eli Lilly and Company: Pharmaceutical Brands 133
Table 49. F. Hoffmann-La Roche: Company Snapshot 134
Table 50. F. Hoffmann-La Roche: Business Segmentation 134
Table 51. F. Hoffmann-La Roche: Revenue, 2017-2019, $ bn 135
Table 52. Gilead Sciences: Company Snapshot 136
Table 53. Gilead Sciences: Main Products 136
Table 54. GlaxoSmithKline: Company Snapshot 138
Table 55. GlaxoSmithKline: Business Segmentation 139
Table 56. GlaxoSmithKline: Product Portfolio 140
Table 57. GlaxoSmithKline: Revenue, 2018-2020, $ bn 141
Table 58. Johnson & Johnson: Company Snapshot 142
Table 59. Johnson & Johnson: Business Segments 142
Table 60. Lonza Group: Company Snapshot 144
Table 61. Lonza Group: Business Segmentation in 2018 144
Table 62. Lonza Group: Product Portfolio 145
Table 63. Lonza Group: Revenue by Region in 2018 145
Table 64. Lupin Limited: Company Snapshot 147
Table 65. Lupin Limited: Business Segmentation 148
Table 66. Merck & Co., Inc.: Company Snapshot 149
Table 67. Merck & Co., Inc.: Business Segmentation 149
Table 68. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 150
Table 69. Novartis International AG: Company Snapshot 151
Table 70. Novartis International AG: Business Segmentation 151
Table 71. Novartis International AG: Revenue, 2017-2019, $ bn 152
Table 72. Novo Nordisk: Company Snapshot 153
Table 73. Novo Nordisk: Product Portfolio 154
Table 74. Patheon Inc.: Company Snapshot 156
Table 75. Patheon Inc.: Business Segmentation in 2018 157
Table 76. Patheon Inc.: Product Portfolio 157
Table 77. Patheon Inc.: Revenue, 2017-2019, $ billion 158
Table 78. Patheon Inc.: Revenue by Region in 2018 158
Table 79. Patheon Inc.: Recent Developments 159
Table 80. Pfizer CentreSource: Company Snapshot 160
Table 81. Pfizer CentreSource: Business Segmentation in 2018 161
Table 82. Pfizer CentreSource: Product Portfolio 161
Table 83. Pfizer CentreSource: Revenue, 2017-2019, $ billion 162
Table 84. Pfizer CentreSource: Revenue by Region in 2018 162
Table 85. Hospira, Inc. (a subsidiary of Pfizer): Company Snapshot 162
Table 86. Pfizer CentreSource: Recent Developments 163
Table 87. Sanofi: Company Snapshot 164
Table 88. Sanofi: Business Segmentation 164
Table 89. Sanofi: Revenue, 2018-2020, $ bn 165
Table 90. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 166



Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032 18
Figure 4. Asia Pacific Pharmaceutical Manufacturing Industry, 2022-2032, $ mn 21
Figure 5. World Healthcare Services Production, annual percentage change 23
Figure 6. Impact of COVID-19 on Business 27
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Pharmaceutical Manufacturing Industry 33
Figure 8. Trends in the Approval of Cancer Therapies by FDA in the Twenty-First Century 36
Figure 9. Leading Causes of Death in the World, 2000 and 2019, million 37
Figure 10. Worldwide Geriatric Population (60 years and above) by Region, 2015 & 2030, million 38
Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 38
Figure 12. Primary Restraints and Impact Factors of Asia Pacific Pharmaceutical Manufacturing Industry 40
Figure 13. Investment Opportunity Analysis 44
Figure 14. Porter’s Fiver Forces Analysis of Asia Pacific Pharmaceutical Manufacturing Industry 47
Figure 15. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, % of Revenue 52
Figure 16. Asia Pacific Addressable Market Cap in 2023-2032 by Formulation, Value ($ mn) and Share (%) 52
Figure 17. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Tablets, 2022-2032, $ mn 53
Figure 18. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Capsules, 2022-2032, $ mn 54
Figure 19. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Injectable, 2022-2032, $ mn 55
Figure 20. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Sprays, 2022-2032, $ mn 56
Figure 21. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Suspensions, 2022-2032, $ mn 57
Figure 22. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Powders, 2022-2032, $ mn 58
Figure 23. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Other Formulations, 2022-2032, $ mn 59
Figure 24. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, % of Sales Revenue 61
Figure 25. Asia Pacific Addressable Market Cap in 2023-2032 by Route of Administration, Value ($ mn) and Share (%) 61
Figure 26. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Oral Medicine, 2022-2032, $ mn 62
Figure 27. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Topical Medicine, 2022-2032, $ mn 63
Figure 28. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Parenteral Medicine, 2022-2032, $ mn 64
Figure 29. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Inhalations, 2022-2032, $ mn 65
Figure 30. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Other Routes of Administration, 2022-2032, $ mn 66
Figure 31. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group, 2022-2032, % of Sales Revenue 68
Figure 32. Asia Pacific Addressable Market Cap in 2023-2032 by Consumer Group, Value ($ mn) and Share (%) 68
Figure 33. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group: Children & Adolescents (17 years old and below), 2022-2032, $ mn 69
Figure 34. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group: Adults (18-64 years old), 2022-2032, $ mn 70
Figure 35. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group: Geriatric (65 years old and above), 2022-2032, $ mn 71
Figure 36. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application, 2022-2032, % of Revenue 73
Figure 37. Asia Pacific Addressable Market Cap in 2023-2032 by Therapeutic Application, Value ($ mn) and Share (%) 73
Figure 38. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Cardiovascular Diseases, 2022-2032, $ mn 74
Figure 39. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Pain, 2022-2032, $ mn 75
Figure 40. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Diabetes, 2022-2032, $ mn 76
Figure 41. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Cancer, 2022-2032, $ mn 77
Figure 42. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Respiratory Diseases, 2022-2032, $ mn 78
Figure 43. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Neurological Diseases, 2022-2032, $ mn 79
Figure 44. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Orthopedics, 2022-2032, $ mn 80
Figure 45. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Other Applications, 2022-2032, $ mn 81
Figure 46. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, % of Revenue 83
Figure 47. Asia Pacific Addressable Market Cap in 2023-2032 by Drug Type, Value ($ mn) and Share (%) 83
Figure 48. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type: Branded Prescription Drugs, 2022-2032, $ mn 84
Figure 49. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type: Generic Prescription Drugs, 2022-2032, $ mn 85
Figure 50. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type: OTC Drugs, 2022-2032, $ mn 86
Figure 51. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel, 2022-2032, % of Revenue 87
Figure 52. Asia Pacific Addressable Market Cap in 2023-2032 by Distribution Channel, Value ($ mn) and Share (%) 88
Figure 53. Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel: Retail Channels, 2022-2032, $ mn 89
Figure 54. Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel: Non-retail Channels, 2022-2032, $ mn 90
Figure 55. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2022-2032, % of Revenue 91
Figure 56. Asia Pacific Addressable Market Cap in 2023-2032 by Manufacturing Facility, Value ($ mn) and Share (%) 92
Figure 57. Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility: In-house Facility, 2022-2032, $ mn 93
Figure 58. Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility: Outsourced Facility, 2022-2032, $ mn 94
Figure 59. Asia-Pacific Pharmaceutical Manufacturing Industry, 2022-2032, $ mn 96
Figure 60. Breakdown of APAC Pharmaceutical Manufacturing Industry by Country, 2022 and 2032, % of Revenue 96
Figure 61. Contribution to APAC 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%) 98
Figure 62. Pharmaceutical Manufacturing Industry in Japan, 2022-2032, $ mn 100
Figure 63. Pharmaceutical Manufacturing Industry in China, 2022-2032, $ mn 102
Figure 64. Pharmaceutical Manufacturing Industry in Australia, 2022-2032, $ mn 104
Figure 65. Pharmaceutical Manufacturing Industry in India, 2022-2032, $ mn 107
Figure 66. Pharmaceutical Manufacturing Industry in South Korea, 2022-2032, $ mn 109
Figure 67. Pharmaceutical Manufacturing Industry in Rest of APAC, 2022-2032, $ mn 111
Figure 68. Growth Stage of Asia Pacific 3D Printing Industry over the Forecast Period 113
Figure 69. Top products of AstraZeneca based on revenue from 2016 to 2019 (in million U.S. dollars) 127
Logo

Asia Pacific Pharmaceutical Manufacturing Industry Outlook, 2029

Contact usWe are friendly and approachable, give us a call.